Literature DB >> 11447994

Apoptosis in the in vivo mammalian forebrain.

K Dikranian1, M J Ishimaru, T Tenkova, J Labruyere, Y Q Qin, C Ikonomidou, J W Olney.   

Abstract

Apoptosis is a word originally introduced by Kerr, Wyllie, and colleagues for a cell death process they defined in terms of its ultrastructural appearance in nonneuronal cells from various tissues. There are very few studies providing detailed ultrastructural criteria for recognizing neuronal apoptosis in the in vivo mammalian brain. In the absence of such criteria, the Kerr/Wyllie description pertaining to nonneuronal cells has served as a reference standard. However, contemporary neurobiologists typically rely on cell culture models for studying neuronal apoptosis, and these models are rarely validated ultrastructurally; rather they are assumed to be appropriate models based on unvalidated biochemical tests for apoptosis. Relying on evidence generated in such cell culture models or on nonspecific cytochemical tests applied to brain tissue, many authors have recently suggested that an apoptotic mechanism may mediate neuronal death in a wide variety of human neurodegenerative diseases. Whether the cell death process in neurodegenerative diseases meets ultrastructural criteria for apoptosis has been given very little consideration. Recently, several methods have been described for triggering extensive apoptotic neurodegeneration in the developing in vivo mammalian brain. These methods include head trauma or treatment with several types of drugs (NMDA antagonists, GABAA agonists, or ethanol). We have performed an ultrastructural analysis of the neuronal cell death process triggered in the cerebral cortex and thalamus by these several methods and compared it with physiological cell death (PCD), a prototypic example of neuronal apoptosis that occurs naturally in the developing brain. Our findings, which are reviewed herein, demonstrate that the types and sequence of changes induced by each of the above methods are identical to those that characterize PCD. This confirms that each of these methods produces bona fide in vivo apoptotic neurodegeneration, and it signifies that our description of this neuronal apoptotic process, which differs in some respects from the Kerr/Wyllie description of nonneuronal apoptosis, can serve as a useful reference standard for recognizing the characteristic changes that in vivo neurons undergo when they are dying by an apoptotic mechanism.

Entities:  

Mesh:

Year:  2001        PMID: 11447994     DOI: 10.1006/nbdi.2001.0411

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  46 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

2.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

3.  Spatiotemporal evolution of apoptotic neurodegeneration following traumatic injury to the developing rat brain.

Authors:  Philip V Bayly; Krikor T Dikranian; Erin E Black; Chainllie Young; Yue-Qin Qin; Joann Labruyere; John W Olney
Journal:  Brain Res       Date:  2006-07-05       Impact factor: 3.252

Review 4.  GABAA receptors, anesthetics and anticonvulsants in brain development.

Authors:  Oliver Henschel; Keith E Gipson; Angelique Bordey
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-04       Impact factor: 4.388

5.  A highly toxic cellular prion protein induces a novel, nonapoptotic form of neuronal death.

Authors:  Heather M Christensen; Krikor Dikranian; Aimin Li; Kathleen C Baysac; Ken C Walls; John W Olney; Kevin A Roth; David A Harris
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

6.  Using animal models to evaluate the functional consequences of anesthesia during early neurodevelopment.

Authors:  Susan E Maloney; Catherine E Creeley; Richard E Hartman; Carla M Yuede; Charles F Zorumski; Vesna Jevtovic-Todorovic; Krikor Dikranian; Kevin K Noguchi; Nuri B Farber; David F Wozniak
Journal:  Neurobiol Learn Mem       Date:  2018-03-14       Impact factor: 2.877

7.  Lithium protects against anesthesia-induced developmental neuroapoptosis.

Authors:  Megan M W Straiko; Chainllie Young; Davide Cattano; Catherine E Creeley; Haihui Wang; Derek J Smith; Stephen A Johnson; Erin S Li; John W Olney
Journal:  Anesthesiology       Date:  2009-04       Impact factor: 7.892

8.  Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats.

Authors:  Megan N Huizenga; Patrick A Forcelli
Journal:  Neurotox Res       Date:  2018-08-24       Impact factor: 3.911

9.  Depletion of calcium stores in injured sensory neurons: anatomic and functional correlates.

Authors:  Geza Gemes; Marcel Rigaud; Paul D Weyker; Stephen E Abram; Dorothee Weihrauch; Mark Poroli; Vasiliki Zoga; Quinn H Hogan
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

10.  Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.

Authors:  Vesna Jevtovic-Todorovic; Richard E Hartman; Yukitoshi Izumi; Nicholas D Benshoff; Krikor Dikranian; Charles F Zorumski; John W Olney; David F Wozniak
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.